MINDway: A Phase Ib/II Dose Optimization Study to Assess Safety and Pharmacokinetics of Tafasitamab plus Lenalidomide in Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma

被引：0
|
作者：
Greil, Richard [1 ,2 ]
Kopeckova, Katerina [3 ,4 ]
Arcaini, Luca [5 ,6 ]
Amin, Aasim [7 ]
de Graaf, Katrien [8 ]
Jegg, Anna-Maria [7 ]
机构：
[1] Paracelsus Med Univ, Salzburg, Austria
[2] Salzburg Canc Res Inst Ctr Clin Canc & Immunol Tr, Canc Cluster, Salzburg, Austria
[3] Charles Univ Prague, Fac Med 2, Dept Oncol, Prague, Czech Republic
[4] Motol Univ Hosp, Prague, Czech Republic
[5] Fdn IRCCS Policlin San Matteo, Div Hematol, Pavia, Italy
[6] Univ Pavia, Dept Mol Med, Pavia, Italy
[7] MorphoSys AG, Clin Dev, Planegg, Germany
[8] MorphoSys AG, Clin Pharmacol, Planegg, Germany
来源：
CLINICAL LYMPHOMA MYELOMA & LEUKEMIA | 2022年 / 22卷
关键词：
ABCL; CD19; tafasitamab; lenalidomide; DLBCL; MINDway; Trial-in-Progress;
D O I：
暂无
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
ABCL-052
引用
收藏
页码：S356 / S356
页数：1
相关论文
共 50 条
  • [1] A Phase 3 Study of Tafasitamab Plus Lenalidomide in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (firmMIND)
    Larsen, Thomas S.
    Manzke, Oliver
    Leibovitz, Daniel
    Arbushites, Michael
    BLOOD, 2022, 140 : 12077 - 12078
  • [2] Clinical Treatment Guidelines for Tafasitamab Plus Lenalidomide in Patients with Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Nedved, Adrienne
    Maddocks, Kami
    Nowakowski, Grzegorz S.
    ONCOLOGIST, 2023, : 199 - 207
  • [3] Tafasitamab for refractory/relapsed diffuse large B-cell lymphoma
    Lu, Q.
    Huang, H.
    Tang, S.
    Wang, Y.
    Yang, D-H
    DRUGS OF TODAY, 2021, 57 (09) : 571 - 580
  • [4] DIFFUSE LARGE B-CELL LYMPHOMA RESPONDS TO TAFASITAMAB PLUS LENALIDOMIDE
    不详
    CANCER DISCOVERY, 2020, 10 (08) : 1091 - 1091
  • [5] Estimation of Long-Term Survival with Tafasitamab plus Lenalidomide in Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Salles, Gilles
    Goswami, Budhaditya
    Bagnardi, Vincenzo
    Dey, Debarshi
    Winderlich, Mark
    Ambarkhane, Sumeet
    Huang, Dan
    Nowakowski, Grzegorz S.
    BLOOD, 2020, 136
  • [6] Tafasitamab for the treatment of relapsed or refractory diffuse large B-cell lymphoma
    Salles, Gilles
    Dlugosz-Danecka, Monika
    Ghesquieres, Herve
    Jurczak, Wojciech
    EXPERT OPINION ON BIOLOGICAL THERAPY, 2021, 21 (04) : 455 - 463
  • [7] Efficacy and safety of lenalidomide in relapsed/refractory diffuse large B-cell lymphoma
    Habermann, T.
    Lossos, I.
    Justice, G.
    Tuscano, J.
    Cole, C.
    Vose, J.
    Pietronigro, D.
    Takeshita, K.
    Ervin-Haynes, A.
    Zeldis, J.
    Wiernik, P.
    ANNALS OF ONCOLOGY, 2008, 19 : 150 - 150
  • [8] Tafasitamab and lenalidomide for relapsed/refractory diffuse large B-cell lymphoma in a patient on chronic intermittent hemodialysis
    Moore, Donald C.
    Eagers, Keren A.
    Janes, Amanda
    Pineda-Roman, Mauricio
    JOURNAL OF ONCOLOGY PHARMACY PRACTICE, 2023, 29 (01) : 239 - 241
  • [9] Five-year subgroup analysis of tafasitamab plus lenalidomide from the phase II L-MIND study in patients with relapsed or refractory diffuse large B-cell lymphoma
    Duell, Johannes
    Abrisqueta, Pau
    Dreyling, Martin H.
    Gaidano, Gianluca
    Barca, Eva Gonzalez
    Jurczak, Wojciech
    Maddocks, Kami J.
    Menne, Tobias
    Tournilhac, Olivier
    Bakuli, Abhishek
    Amin, Aasim
    Gurbanov, Konstantin
    Salles, Gilles A.
    Nagy, Zsolt
    JOURNAL OF CLINICAL ONCOLOGY, 2023, 41 (16)
  • [10] Five-Year Subgroup Analysis of Tafasitamab plus Lenalidomide From the Phase II L-MIND Study in Patients With Relapsed or Refractory Diffuse Large B-Cell Lymphoma
    Duell, Johannes
    Abrisqueta, Pau
    Dreyling, Martin
    Gaidano, Gianluca
    Gonzalez Barca, Eva
    Jurczak, Wojciech
    Maddocks, Kami J.
    Menne, Tobias
    Nagy, Zsolt
    Tournilhac, Olivier
    Bakuli, Abhishek
    Amin, Aasim
    Gurbanov, Konstantin
    Salles, Gilles
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2023, 23 : S436 - S437
12345